Department of Internal Medicine, Harran University Faculty of Medicine, Sanliurfa, Turkey.
Eur J Intern Med. 2011 Jun;22(3):249-53. doi: 10.1016/j.ejim.2010.12.003. Epub 2011 Jan 7.
Diabetes is associated with abnormalities in lipid profile and increased oxidative stress. Statins are preferred agents in diabetic patients due to their antioxidant and LDL-C lowering effects. This study is designed to compare the effects of atorvastatin and rosuvastatin on low density lipoprotein cholesterol (LDL-C), lipid hydroperoxide (LOOH), total oxidant status (TOS) and total antioxidant capacity (TAC) in diabetic patients with hyperlipidemia.
Sixty two patients who have type 2 diabetes mellitus with serum LDL levels more than 100mg/dL were randomly assigned to receive atorvastatin 20mg (n=31) or rosuvastatin 10mg (n=31). Blood tests were performed at the beginning of the study and after three months.
There were no statistically significant differences in the pre- and after treatment levels of the LDL-C between groups. TAC values were increased in both groups and statistically significant in the former group (p=0.007). There was no difference between the change percentages ((after treatment TAC-pretreatment TAC)/pretreatment level) of TAC between two treatment groups. The effects of two drugs on the other oxidative parameters were not significantly different.
Both atorvastatin and rosuvastatin may be helpful in reducing increased oxidative stress in diabetic patients with hyperlipidemia.
糖尿病与脂质谱异常和氧化应激增加有关。由于具有抗氧化和降低 LDL-C 的作用，他汀类药物是糖尿病患者的首选药物。本研究旨在比较阿托伐他汀和瑞舒伐他汀对伴有高血脂的糖尿病患者的低密度脂蛋白胆固醇（LDL-C）、脂质过氧化物（LOOH）、总氧化剂状态（TOS）和总抗氧化能力（TAC）的影响。
62 名患有 2 型糖尿病且血清 LDL 水平高于 100mg/dL 的患者被随机分为阿托伐他汀 20mg 组（n=31）或瑞舒伐他汀 10mg 组（n=31）。在研究开始时和三个月后进行血液检查。
两组 LDL-C 的治疗前后水平无统计学差异。两组的 TAC 值均升高，且前者有统计学意义（p=0.007）。两组 TAC 的变化百分比（（治疗后 TAC-治疗前 TAC）/治疗前水平）之间无差异。两种药物对其他氧化参数的影响无显著差异。
阿托伐他汀和瑞舒伐他汀均可有助于降低伴有高血脂的糖尿病患者的氧化应激增加。
